The role of vaccines in the control of STDs: HPV vaccines

Genitourinary Medicine

Volumn 72, Issue 6, 1996, Pages 398-403

  Frazer, Ian H ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

cancer; cervix; papillomavirus; vaccines; warts

Indexed keywords

VIRUS VACCINE;

CONDYLOMA; HUMAN; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

EID: 0030446516     PISSN: 02664348     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.72.6.398     Document Type: Review

References (65)

1. Evander M, Edlund K, Gustafsson Å, Jonsson M, Karlsson R, Rylander E, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995;171:1026-30.
2. De Roda Husman AM, Walboomers JMM, Hopman E, Bleker OP, Heimerhorst TMJ, Rozendaal L, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol 1995;46:97-102.
3. Baken LA, Koutsky LA, Kuypers J, Kosorok MR, Lee S-K, Kiviat NB, et al. Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J Infect Dis 1995;171:429-32.
4. De Villiers E-M. Human pathogenic papillomavirus types: An update. Curr Top Microbiol Immunol 1994;186:1-12.
5. Hippeläinen M, Syrjänen S, Koskela H, Pulkkinen J, Saarikoski S, Syrjänen K. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis 1993;20:321-8.
6. Kiviat NB, Koutsky LA, Paavonen JA, Galloway DA, Critchlow CW, Beckmann AM, et al. Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. J Infect Dis 1989;159:293-302.
7. Hellberg D, Borendal N, Sikström B, Nilsson S, Mårdh PA. Comparison of women with cervical human papillomavirus infection and genital warts. I. Some behavioural factors and clinical findings. Genitourin Med 1995;71:88-91.
8. Chirgwin KD, Feldman J, Augenbraun M, Landesman S, Minkoff H. Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women. J Infect Dis 1995;172:235-8.
9. Jamison JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas JM Jr. Spectrum of genital human papillomavirus infection in a female adolescent population. Sex Transm Dis 1995;22:236-43.
10. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments], J Natl Cancer Inst 1995;87:796-802.
11. Parkin DM. Cancer in developing countries. Cancer Surv 1994;19-20:519-61.
12. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995;76:1888-901.
13. Schiffman MH. Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol 1994;186:55-81.
14. Critchlow CW, Koutsky LA. Epidemiology of Human Papillomavirus Infection. In: Mindel A, ed Genital Warts Human Papillomavirus Infection. London: Edward Arnold, 1995:53-81.
15. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin Infect Dis 1995;20:S91-S97.
16. Fredricks BD, Balkin A, Daniel HW, Schonrock J, Ward B, Frazer IH. Transmission of human papillomaviruses from mother to child. Aust NZ J Obstet Gynaecol 1993;33:30-32.
17. Cason J, Kaye JN, Jewers RJ, Kambo PK, Bible JM, Kell B, et al. Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. J Med Virol 1995;47:209-18.
18. Jarrett WFH, O'Neil BW, Gaukroger JM, Laird HM, Smith KT, Campo MS. Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet Rec 1990;126:449-52.
19. Jarrett WFH, O'Neil BW, Gaukroger JM, Smith KT, Laird HM, Campo MS. Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet Rec 1990;126:473-5.
20. Durst M, Gissmann L, Ikenberg H, Zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983;80:3812-5.
21. Zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994;186:131-56.
22. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MAN, Finch J, et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995;206:126-35.
23. Hofmann KJ, Cook JC, Joyce JG, Brown DR, Schultz LD, George HA, et al. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 1995;209:506-18.
24. Kimbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-41.
25. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993;67:1936-44.
26. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-7.
27. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-22.
28. Christensen ND, Höpfl R, DiAngelo SL, Cladel NM, Patrick SD, Welsh PA, et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994;75:2271-6.
29. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995;13:1509-14.
30. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
31. Bell JA, Sundberg JP, Ghim S, Newsome J, Jenson AB, Schlegel R. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 1994;62:194-8.
32. Hines JF, Ghim SJ, Schlegel R, Jenson AB. Prospects for a vaccine against human papillomavirus. Obstet Gynecol 1995;86:860-6.
33. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-5.
34. Christensen ND, Kirnbauer R, Schiller JT, Ghim S-J, Schlegel R, Jenson AB, et al. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 1994;205:329-35.
35. Chan S-Y, Delius H, Halpern AL, Bernard H-U. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 1995;69:3074-83.
36. Icenogle JP, Sathya P, Miller DL, Tucker RA, Rawls WE. Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16. Virology 1991;184:101-7.
37. Ramesar JE, Rybicki EP, Williamson AL. Sequence variation in the L1 gene of human papillomavirus type 16 from Africa. Arch Virol 1995;140:1863-70.
38. Yamada T, Wheeler CM, Halpern AL, Stewart ACM, Hildesheim A, Jenison SA. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 1995;69:7743-53.
39. Cheng G, Icenogle JP, Kirnbauer R, Hubbert NL, St Louis ME, Han CL, et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis 1995;172:1584-7.
40. Galloway DA. Navigating the descent into papillomavirus hell. J Infect Dis 1994;170:1075-6.
41. Wikström A, Van Doornum GJJ, Quint WGV, Schiller JT, Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol 1995;76:529-39.
42. Melbye M, Palefsky J, Gonzales J, Ryder LP, Nielsen H, Bergmann O, et al. Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities. Int J Cancer 1990;46:203-6.
43. Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, Kupsch E, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994;57:836-40.
44. Bird GL, Smith H, Portmann B, Alexander GJ, Williams R. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers [see comments]. Q J Med 1989;73:895-902.
45. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
46. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994;75:2075-9.
47. Roden RBS, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 1995;69:5147-51.
48. Christensen ND, Kreider JW, Shah KV, Rando RF. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992;73:1261-7.
49. Kennedy L, Buntine DW, O'Connor DT, Frazer IH. Human papillomavirus - a male consort study. Med J Aust 1988;149:309-11.
50. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, et al. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
51. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994;76:959-62.
52. Schwarz A, Bhardwaj R, Aragane Y, Mahnke K, Riemann H, Metze D, et al. Ultraviolet-B-induced apoptosis of keratinocytes: evidence for partial involvement of tumor necrosis factor-α in the formation of sunburn cells. J Invest Dermatol 1995;104:922-7.
53. Crum CP, Nuovo G, Friedman D, Silverstein SJ. Accumulation of RNA homologous to human papillomavirus type 16 open reading frames in genital precancers. J Virol 1988;62:84-90.
54. Wettstein FO, Barbosa MS, Nasseri M. Identification of the major cottontail rabbit papillomavirus late RNA cap site and mapping and quantitation of an E2 and minor E6 coding mRNA in papillomas and carcinomas. Virology 1987;159:321-8.
55. Zur Hausen H. Papillomaviruses in human cancer. Appl Pathol 1987;5:19-24.
56. Pater MM, Pater A. Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix. Virology 1985;145:313-8.
57. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis KE. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989;81:1698-704.
58. Tindle RW, Frazer IH. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr Top Microbiol Immunol 1994;186:217-53.
59. Selvakumar R, Borenstein LA, Lin Y-L, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 1995;69:602-5.
60. McGarvie GM, Grindlay GJ, Chandrachud LM, O'Neil BW, Jarrett WFH, Campo MS. T cell responses to BPV-4 E7 during infection and mapping of T cell epitopes. Virology 1995;206:504-10.
61. Feltkamp MCW, Vreugdenhil GR, Vierboom RPM, Ras E, Van der Burg SH, Ter Schegget J, et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995;25:2638-42.
62. Chen L, Mizuno MT, Singhal MC, Hu S-L, Galloway DA, Hellström I, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 onco-protein of human papillomavirus type 16. J Immunol 1992;148:2617-21.
63. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-61.
64. Nishioka WK, Welsh RM. Susceptibility to cytotoxic T lymphocyte-induced apoptosis is a function of the proliferative status of the target. J Exp Med 1994;179:769-74.
65. Frazer IH, McMillan NJ. Papillomatosis and condyloma accumulate. In: Stuart-Harris R, Penny R, eds. Clinical Applications of the Interferons London: Chapman and Hall 1997.